<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012246</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068497</org_study_id>
    <secondary_id>UTMB-00-297</secondary_id>
    <secondary_id>NCI-931</secondary_id>
    <nct_id>NCT00012246</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract</brief_title>
  <official_title>A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

      PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in
      treating patients who have cancer of the gastrointestinal tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether immunization with carcinoembryonic antigen (CEA) peptide 1-6D (CAP
           1-6D) emulsified in Montanide ISA-51 adjuvant or dissolved in sargramostim (GM-CSF) can
           generate CAP 1-6D-specific T cells in patients with CEA-producing adenocarcinomas of
           gastrointestinal tract origin.

        -  Determine whether vaccination with CAP 1-6D can generate cytotoxic T cells against
           CEA-expressing tumors in these patients.

        -  Determine whether this vaccine can produce antitumor responses in these patients.

        -  Determine the frequency and severity of toxic effects associated with this vaccine in
           these patients.

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive carcinoembryonic antigen peptide 1-6D (CAP 1-6D) emulsified in
           Montanide ISA-51 adjuvant subcutaneously on day 1.

        -  Arm II: Patients receive CAP 1-6D dissolved in sargramostim (GM-CSF) intradermally on
           day 1.

      Treatment repeats in both arms every 3 weeks for 6 courses in the absence of disease
      progression or unacceptable toxicity.

      Patients are followed at 3 weeks and then as necessary.

      PROJECTED ACCRUAL: A total of 10-36 patients (5-18 per arm) will be accrued for this study
      within 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively Terminated
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Production of CAP 1-6D T cells</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Production of cytotoxic T cells</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of toxic effects</measure>
  </primary_outcome>
  <enrollment type="Actual">7</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Extrahepatic Bile Duct Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>carcinoembryonic antigen peptide 1-6D</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage II, III, or IV adenocarcinoma of the gastrointestinal
             tract originating in 1 of the following:

               -  Esophagus

               -  Stomach

               -  Pancreas

               -  Small intestine

               -  Colon or rectum

               -  Gall bladder

               -  Extrahepatic bile ducts

               -  Ampulla of Vater

          -  Completed standard therapy and at risk of recurrent disease OR has relatively stable
             metastatic disease and a life expectancy of at least 6 months

          -  Carcinoembryonic antigen (CEA)-producing tumor as evidenced by detectable blood levels
             of CEA or positive for CEA on immunohistochemical staining

          -  Human Leukocyte Antigen (HLA)-A2+

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Southwest Oncology Group (SWOG) 0-1

        Life expectancy:

          -  See Disease Characteristics

        Hematopoietic:

          -  White Blood Count (WBC) at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 8 g/dL

        Hepatic:

          -  Serum Glutamic Oxalacetic Transaminase (SGOT) or Serum Glutamic Pyruvic Transaminase
             (SGPT) no greater than 3 times upper limit of normal

          -  Hepatitis B and C negative

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Other:

          -  No other prior malignancy unless currently disease free and off all therapy for that
             malignancy

               -  Early skin cancer allowed

          -  No AIDS

          -  HIV negative

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 30 days after study
             participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior immunotherapy

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

        Surgery:

          -  At least 4 weeks since prior surgery

        Other:

          -  No other concurrent therapy for malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P. Whitehead, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 15, 2013</last_update_submitted>
  <last_update_submitted_qc>May 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>localized gallbladder cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>localized extrahepatic bile duct cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>adenocarcinoma of the gallbladder</keyword>
  <keyword>adenocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

